AU Patent

AU2022211008A1 — Combination therapy schedules to treat cancer

Assigned to University of Texas System · Expires 2023-08-31 · 3y expired

What this patent protects

Aspects of the present disclosure are directed to methods for treating a subject having cancer. Certain aspects relate to treatment with an anthracene derivative after treatment with one or more pyrimidine analog antimetabolites. Further aspects relate to methods for improving th…

USPTO Abstract

Aspects of the present disclosure are directed to methods for treating a subject having cancer. Certain aspects relate to treatment with an anthracene derivative after treatment with one or more pyrimidine analog antimetabolites. Further aspects relate to methods for improving the efficacy of one or more pyrimidine analog antimetabolites by administering to a subject a therapeutically effective amount of an anthracene derivative after administration of the one or more pyrimidine analog antimetabolites.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022211008A1
Jurisdiction
AU
Classification
—
Expires
2023-08-31
Drug substance claim
No
Drug product claim
No
Assignee
University of Texas System
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.